SeaSpine announced preliminary 2Q17 revenue in the range of US $34.0MM to $34.2MM, +3% vs. 2Q16. (U.S. $30.4MM, +1%, ex-U.S. $3.8MM, +0.2%)
Based on SeaSpine’s estimates, quarterly and 1H17 revenues by segment are expected to approximate the following:
2Q17
2Q16
$ Change
% Change
Spine
$16.6
$16.4
$0.2
1.2%
Orthobiologics
$17.6
$16.8
$0.8
4.7%
Total
$34.2
$33.2
$1.0
3.0%
1H17
1H16
$ Change
% Change
Spine
$31.4
$31.1
$0.2
0.7%
Orthobiologics
$34.7
$33.5
$1.3
3.8%
Total
$66.1
$64.6
$1.5
2.3%
The company’s recent completion of full commercial launch of its Mariner Posterior Fixation system reflects its continuing focus on expanding its product portfolio.
SeaSpine announced preliminary 2Q17 revenue in the range of US $34.0MM to $34.2MM, +3% vs. 2Q16. (U.S. $30.4MM, +1%, ex-U.S. $3.8MM, +0.2%)
Based on SeaSpine's estimates, quarterly and 1H17 revenues by segment are expected to approximate the following:
Q17 Q16 $...
SeaSpine announced preliminary 2Q17 revenue in the range of US $34.0MM to $34.2MM, +3% vs. 2Q16. (U.S. $30.4MM, +1%, ex-U.S. $3.8MM, +0.2%)
Based on SeaSpine’s estimates, quarterly and 1H17 revenues by segment are expected to approximate the following:
2Q17
2Q16
$ Change
% Change
Spine
$16.6
$16.4
$0.2
1.2%
Orthobiologics
$17.6
$16.8
$0.8
4.7%
Total
$34.2
$33.2
$1.0
3.0%
1H17
1H16
$ Change
% Change
Spine
$31.4
$31.1
$0.2
0.7%
Orthobiologics
$34.7
$33.5
$1.3
3.8%
Total
$66.1
$64.6
$1.5
2.3%
The company’s recent completion of full commercial launch of its Mariner Posterior Fixation system reflects its continuing focus on expanding its product portfolio.
Copy to clipboard 
